Ekkehard Mössner

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

Ekkehard Mössner, Peter Brünker, Samuel Moser et al. · Blood · 2010 · 929 citations · Full text

Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions

Tilman Schlothauer, Sylvia Herter, Claudia Ferrara et al. · Protein Engineering Design and Selection · 2016 · 388 citations · Full text

Immunology, Immune Regulation, Immunodominance +24

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

Christian Klein, Alfred Lammens, Wolfgang Schäfer et al. · mAbs · 2013 · 366 citations · Full text

Immunology, Immunodominance, Pathology +18

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy

Christina Claus, Claudia Ferrara, Wei Xu et al. · Science Translational Medicine · 2019 · 252 citations · Full text

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

Gerhard Niederfellner, Alfred Lammens, Olaf Mundigl et al. · Blood · 2011 · 227 citations · Full text